502 reports of this reaction
2.3% of all FESOTERODINE FUMARATE reports
#7 most reported adverse reaction
URINARY RETENTION is the #7 most commonly reported adverse reaction for FESOTERODINE FUMARATE, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 502 FDA adverse event reports linking FESOTERODINE FUMARATE to URINARY RETENTION. This represents approximately 2.3% of all 22,165 adverse event reports for this drug.
Patients taking FESOTERODINE FUMARATE who experience urinary retention should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
URINARY RETENTION is a less commonly reported adverse event for FESOTERODINE FUMARATE, but still significant enough to appear in the safety profile.
In addition to urinary retention, the following adverse reactions have been reported for FESOTERODINE FUMARATE:
The following drugs have also been linked to urinary retention in FDA adverse event reports:
URINARY RETENTION has been reported as an adverse event in 502 FDA reports for FESOTERODINE FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
URINARY RETENTION accounts for approximately 2.3% of all adverse event reports for FESOTERODINE FUMARATE, making it a notable side effect.
If you experience urinary retention while taking FESOTERODINE FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.